The U.S. Food and Drug Administration approved Boehringer Ingelheim’s Jascayd (nerandomilast), a preferential PDE4B inhibitor, for idiopathic pulmonary fibrosis (IPF), marking the first new FDA approval in the indication in more than ten years. Boehringer reported phase III data showing a slowed decline in lung function versus placebo and a tolerability profile management may prefer over older agents. Jascayd gives clinicians an oral alternative for a rare, progressive fibrosing lung disease. The approval follows a priority review and adds to Boehringer’s established IPF portfolio, where Ofev has been a commercial staple. Analysts characterized the approval as a modest but meaningful advance, noting the crowded landscape of experimental IPF drugs and remaining need for agents with stronger efficacy and tolerability profiles. Regulatory and commercialization teams will be watching uptake dynamics and how clinicians sequence Jascayd alongside or instead of existing antifibrotic therapies. The approval may also spur further investment and competition in the IPF pipeline.